Author: Ken Dropiewski

Medtronic TYRX™ Absorbable Antibacterial Envelope Is Effective at Reducing Infections in Cardiac Device Patients with Hematomas

DUBLIN, July 26, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study published in Heart Rhythm, demonstrating a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) is […]

Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive […]

Philips delivers Q2 sales of EUR 4.2 billion, with 9% comparable sales growth; net income amounts to EUR 153 million and Adjusted EBITA margin improves 280 basis points to 12.6%; company announces EUR 1.5 billion share buyback program

July 26, 2021 Second-quarter highlights Group sales increased to EUR 4.2 billion, with 9% comparable sales growth Comparable order intake decreased 15%, with strong double-digit growth in the Diagnosis & Treatment businesses and a decline in the Connected Care businesses on the back of COVID-19-related 167% growth in Q2 2020 […]

CARMAT Announces the First Human Implant of its Aeson® Artificial Heart in Germany

The implant was performed at Hannover Medical School PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic […]

Texas Cardiac Arrhythmia Institute leader participates in clinical trial for world’s first artificial intelligence technology for complex cardiac arrhythmia procedures

AUSTIN, Texas, July 22, 2021 /PRNewswire/ — The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center recently led a clinical study to evaluate the world’s first data-driven artificial intelligence (AI) platform for cardiac electrophysiology (EP) procedures. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, conducted the […]

Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR

IRVINE, Calif., July 22, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that clinical and economic results from the 3M (multidisciplinary, multimodality, but minimalist) Transcatheter Aortic Valve Replacement (TAVR) Economic Study and the PARTNER 3 Bicuspid Registry for SAPIEN 3 TAVR Study were presented at TVT 2021: The Structural Heart Summit. The 3M-TAVR study demonstrated positive […]

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Company’s […]

Galaxy Medical’s ECLIPSE-AF Study 90 Day Remapping Results to be Featured at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat

SAN CARLOS, Calif., July 22, 2021 /PRNewswire/ — Galaxy Medical announced today that the 90 day remapping results of its ECLIPSE-AF study will be featured at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27th.  Ante Anić, M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of […]

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

CPC to Manage Planning, Organization, and Day-to-Day Execution of the Trial LAS VEGAS, July 22, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization […]